Back to Search Start Over

Respiratory symptoms and respiratory deaths: A multi-cohort study with 45 years observation time.

Authors :
Stavem K
Johannessen A
Nielsen R
Gulsvik A
Source :
PloS one [PLoS One] 2021 Nov 22; Vol. 16 (11), pp. e0260416. Date of Electronic Publication: 2021 Nov 22 (Print Publication: 2021).
Publication Year :
2021

Abstract

This study determined the association between respiratory symptoms and death from respiratory causes over a period of 45 years. In four cohorts of random samples of Norwegian populations with 103,881 participants, 43,731 persons had died per 31 December 2016. In total, 5,949 (14%) had died from respiratory diseases; 2,442 (41%) from lung cancer, 1,717 (29%) chronic obstructive pulmonary disease (COPD), 1,348 (23%) pneumonia, 119 (2%) asthma, 147 (2%) interstitial lung disease and 176 (3%) other pulmonary diseases. Compared with persons without respiratory symptoms the multivariable adjusted hazard ratio (HR) for lung cancer deaths increased with score of breathlessness on effort and cough and phlegm, being 2.6 (95% CI 2.1-3.2) for breathlessness score 3 and 2.1 (95% CI 1.7-2.5) for cough and phlegm score 5. The HR of COPD death was 6.4 (95% CI 5.4-7.7) for breathlessness score 3 and 3.0 (2.4-3.6) for cough and phlegm score 5. Attacks of breathlessness and wheeze score 2 had a HR of 1.6 (1.4-1.9) for COPD death. The risk of pneumonia deaths increased also with higher breathlessness on effort score, but not with higher cough and phlegm score, except for score 2 with HR 1.5 (1.2-1.8). In this study with >2.4 million person-years at risk, a positive association was observed between scores of respiratory symptoms and deaths due to COPD and lung cancer. Respiratory symptoms are thus important risk factors, which should be followed thoroughly by health care practitioners for the benefit of public health.<br />Competing Interests: I have read the journal’s policy and the authors of this manuscript have the following competing interests: RN reports grants and personal fees from AstraZeneca, grants from GlaxoSmithKline, grants from Boehringer Ingelheim, outside the submitted work. All other authors have declared that no competing interests exist. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

Details

Language :
English
ISSN :
1932-6203
Volume :
16
Issue :
11
Database :
MEDLINE
Journal :
PloS one
Publication Type :
Academic Journal
Accession number :
34807953
Full Text :
https://doi.org/10.1371/journal.pone.0260416